Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,307
Out of 4,667 analysts
11
Total ratings
n/a
Success rate
-27.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.98 | +304.04% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $15.02 | +133.02% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $9.59 | +87.70% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.44 | +103.49% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $6.04 | -0.66% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.18 | +180.90% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $18 | $0.31 | +5,801.64% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $56.09 | -60.78% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $20.01 | +19.94% | 1 | Dec 19, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | $10 | $11.49 | -12.97% | 1 | Oct 26, 2021 |
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.98
Upside: +304.04%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $15.02
Upside: +133.02%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $9.59
Upside: +87.70%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.44
Upside: +103.49%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $6.04
Upside: -0.66%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.18
Upside: +180.90%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $18
Current: $0.31
Upside: +5,801.64%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $56.09
Upside: -60.78%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $20.01
Upside: +19.94%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.49
Upside: -12.97%